NYSE:CTLT - Catalent Stock Price, News, & Analysis

Catalent trades on the New York Stock Exchange (NYSE) under the ticker symbol "CTLT."

Catalent Inc (NYSE:CTLT) issued its earnings results on Tuesday, February, 5th. The company reported $0.45 earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of $0.37 by $0.08. The business earned $623 million during the quarter, compared to the consensus estimate of $608.38 million. Catalent had a net margin of 5.48% and a return on equity of 17.42%. Catalent's revenue was up 2.8% on a year-over-year basis. During the same period last year, the business posted $0.45 EPS. View Catalent's Earnings History.

Catalent is scheduled to release their next quarterly earnings announcement on Tuesday, May 7th 2019. View Earnings Estimates for Catalent.

Catalent will be holding an earnings conference call on Tuesday, May 7th at 8:15 AM Eastern. Interested parties can register for or listen to the call using this link.

Catalent issued an update on its FY 2019 earnings guidance on Tuesday, February, 5th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $2.5-2.59 billion, compared to the consensus revenue estimate of $2.51 billion.

7 equities research analysts have issued 12-month price objectives for Catalent's stock. Their forecasts range from $45.00 to $55.00. On average, they anticipate Catalent's share price to reach $50.50 in the next twelve months. This suggests a possible upside of 13.2% from the stock's current price. View Analyst Price Targets for Catalent.

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Catalent in the last year. There are currently 1 hold rating and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Catalent.

Media coverage about CTLT stock has been trending negative on Friday, according to InfoTrie Sentiment. The research group identifies positive and negative news coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Catalent earned a media sentiment score of -2.2 on InfoTrie's scale. They also gave news headlines about the company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an impact on the stock's share price in the next several days.

Some companies that are related to Catalent include UCB (UCBJF), BioMarin Pharmaceutical (BMRN), Teva Pharmaceutical Industries (TEVA), Ono Pharmaceutical (OPHLF), Merck KGaA (MKGAF), Mylan (MYL), GRIFOLS S A/S (GRFS), Genmab A/S (GNMSF), Ionis Pharmaceuticals (IONS), Alnylam Pharmaceuticals (ALNY), Marina Biotech (MRNA), Sarepta Therapeutics (SRPT), Bausch Health Companies (BHC), SAGE Therapeutics (SAGE) and Jazz Pharmaceuticals (JAZZ).

Based on aggregate information from My MarketBeat watchlists, some companies that other Catalent investors own include Energy Transfer LP Unit (ET), Abbott Laboratories (ABT), AbbVie (ABBV), Exelixis (EXEL), Gilead Sciences (GILD), GW Pharmaceuticals PLC- (GWPH), Horizon Pharma (HZNP), Micron Technology (MU), Alibaba Group (BABA) and CBL & Associates Properties (CBL).

Catalent's stock is owned by a variety of of institutional and retail investors. Top institutional investors include CWM LLC (0.19%), Pier Capital LLC (0.15%), Retirement Systems of Alabama (0.13%), Oppenheimer Asset Management Inc. (0.05%), Brinker Capital Inc. (0.03%) and Louisiana State Employees Retirement System (0.03%). Company insiders that own Catalent stock include Aristippos Gennadios, Barry Littlejohns, Christine Dolan, Donald E Morel, Jr, John J Greisch, John R Chiminski, Lance Miyamoto, Steven L Fasman, Uwe Roehrhoff and William Downie. View Institutional Ownership Trends for Catalent.

CTLT stock was sold by a variety of institutional investors in the last quarter, including Meeder Asset Management Inc., Virtu Financial LLC, Foundry Partners LLC, First Hawaiian Bank, Oppenheimer Asset Management Inc., Strs Ohio and New England Research & Management Inc.. Company insiders that have sold Catalent company stock in the last year include Aristippos Gennadios, Barry Littlejohns, John R Chiminski, Lance Miyamoto, Steven L Fasman and William Downie. View Insider Buying and Selling for Catalent.

CTLT stock was purchased by a variety of institutional investors in the last quarter, including Pier Capital LLC, Sciencast Management LP, CWM LLC, Brinker Capital Inc., We Are One Seven LLC, Nisa Investment Advisors LLC, Los Angeles Capital Management & Equity Research Inc. and Financial Gravity Wealth Inc.. Company insiders that have bought Catalent stock in the last two years include Donald E Morel, Jr, John J Greisch and Uwe Roehrhoff. View Insider Buying and Selling for Catalent.

Shares of CTLT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of CTLT stock can currently be purchased for approximately $44.63.

Catalent has a market capitalization of $6.50 billion and generates $2.46 billion in revenue each year. The company earns $83.60 million in net income (profit) each year or $1.59 on an earnings per share basis. Catalent employs 10,700 workers across the globe.

The official website for Catalent is http://www.catalent.com.

Catalent's mailing address is 14 SCHOOLHOUSE ROAD, SOMERSET NJ, 08873. The company can be reached via phone at 732-537-6200 or via email at [email protected]